Comparison of Intravitreal Ranibizumab and Bevacizumab Treatment for CNV
Authors:
Open Access
- 20 June 2018
- journal article
- Published by Crimson Publishers in Medical & Surgical Ophthalmology Research
- Vol. 2 (3) , 1-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye, 2010
- Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical TrialAmerican Journal of Ophthalmology, 2009
- Economic Implications of Current Age-Related Macular Degeneration TreatmentsOphthalmology, 2009
- One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese PatientsOphthalmology, 2008
- Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2006
- Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfinGraefe's Archive for Clinical and Experimental Ophthalmology, 2005
- Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfinAmerican Journal of Ophthalmology, 2002
- The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of ageOphthalmology, 1998